Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.60 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16580110 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAMAPK1GAA | |
| SCHEMBL4139212 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAMAPK1GAA | |
| SCHEMBL16580430 | 0.91 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAMAPK1LMNA | |
| SCHEMBL9965336 | 0.91 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAMAPK1LMNA | |
| SCHEMBL11936626 | 0.91 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAMAPK1LMNA | |
| SCHEMBL11936652 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22636039 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936625 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14331633 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26090455 | 0.83 | LMNA (0.66) | FOLH1NAALAD2RIMKLAMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885NAALAD2 3/4885RIMKLA 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.